Development of Pneumocystis carinii pneumonia in patients with immunobullous and connective tissue disease receiving immunosuppressive medications.
BACKGROUND
Pneumocystis carinii pneumonia (PCP) causes morbidity and mortality in immunocompromised hosts. Data describing use of PCP prophylaxis in immunosuppressed dermatologic patients are lacking.


OBJECTIVE
We sought to describe the frequency of PCP among dermatologic patients receiving immunosuppression for immunobullous disease or connective tissue disease.


METHODS
We retrospectively reviewed the cases of patients with immunobullous and connective tissue disease at our department of dermatology between 1980 and 2006 who received immunosuppression and had subsequent development of pneumonia. We recorded patient characteristics, use of PCP prophylaxis, whether PCP developed, and if so, their morbidity and mortality.


RESULTS
Of 334 patients identified, 7 (2.1%) were given the diagnosis of PCP during immunosuppressive treatment. Of these 7 patients, 3 (43%) died within 1 month of diagnosis, and none received PCP prophylaxis.


CONCLUSIONS
Retrospective study design and limited patient group are limitations.


CONCLUSIONS
PCP prophylaxis may improve outcomes for some patients with immunobullous or connective tissue disease receiving immunosuppressive therapy.
Gerhart
Jacqueline L
JL
Mayo Medical School, College of Medicine, Rochester, Minnesota 55905, USA.
Kalaaji
Amer N
AN
D003240:Connective Tissue Diseases / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011020:Pneumonia, Pneumocystis / Q000276:immunology* / Q000517:prevention & control; D012307:Risk Factors; D012872:Skin Diseases, Vesiculobullous / Q000150:complications / Q000188:drug therapy* / Q000276:immunology
D007166:Immunosuppressive Agents